PHIO Q3 2024 Earnings — Phio Pharmaceuticals Corp. Revenue & Financial Results | Market Cap Arena

PHIOPhio Pharmaceuticals Corp.

$13M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$644,000

Operating Income

-$2M

Net Income

-$2M

EPS (Diluted)

$-1.54

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$52,000

Balance Sheet

Total Assets

$6M

Total Liabilities

$919,000

Stockholders' Equity

$5M

Cash & Equivalents

$5M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$644,000	-$2M	+64.4%
Operating Income	-$2M	-$3M	+42.7%
Net Income	-$2M	-$3M	+45.2%